Aberdeen Group plc Boosts Holdings in Ventas, Inc. $VTR

Aberdeen Group plc grew its stake in Ventas, Inc. (NYSE:VTR) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,714,166 shares of the real estate investment trust’s stock after purchasing an additional 133,243 shares during the quarter. Aberdeen Group plc owned approximately 0.36% of Ventas worth $132,642,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Arbor Capital Management Inc. ADV boosted its holdings in Ventas by 0.6% in the 3rd quarter. Arbor Capital Management Inc. ADV now owns 21,716 shares of the real estate investment trust’s stock worth $1,520,000 after buying an additional 137 shares during the last quarter. True Wealth Design LLC raised its stake in Ventas by 32.0% in the 4th quarter. True Wealth Design LLC now owns 569 shares of the real estate investment trust’s stock valued at $44,000 after purchasing an additional 138 shares during the last quarter. Foundations Investment Advisors LLC raised its stake in Ventas by 3.3% in the 3rd quarter. Foundations Investment Advisors LLC now owns 4,447 shares of the real estate investment trust’s stock valued at $311,000 after purchasing an additional 144 shares during the last quarter. Checchi Capital Advisers LLC lifted its holdings in Ventas by 3.9% in the 3rd quarter. Checchi Capital Advisers LLC now owns 4,603 shares of the real estate investment trust’s stock valued at $322,000 after purchasing an additional 174 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Ventas by 4.6% in the 3rd quarter. Parallel Advisors LLC now owns 3,970 shares of the real estate investment trust’s stock valued at $278,000 after purchasing an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 94.18% of the company’s stock.

Ventas Stock Up 1.5%

NYSE VTR opened at $83.28 on Friday. The business’s fifty day simple moving average is $83.40 and its 200-day simple moving average is $77.82. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 1.03. The firm has a market cap of $39.55 billion, a PE ratio of 154.22, a P/E/G ratio of 2.02 and a beta of 0.75. Ventas, Inc. has a 52 week low of $60.15 and a 52 week high of $88.36.

Ventas (NYSE:VTR) last announced its quarterly earnings data on Thursday, February 5th. The real estate investment trust reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.89 by ($0.74). Ventas had a net margin of 4.31% and a return on equity of 2.09%. The firm had revenue of ($1,229.71) million during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period in the prior year, the company posted $0.81 EPS. The company’s revenue for the quarter was up 21.7% compared to the same quarter last year. Ventas has set its FY 2026 guidance at 3.780-3.880 EPS. As a group, equities analysts anticipate that Ventas, Inc. will post 3.4 earnings per share for the current year.

Ventas Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 16th. Investors of record on Tuesday, March 31st will be issued a $0.52 dividend. This is a boost from Ventas’s previous quarterly dividend of $0.48. This represents a $2.08 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, March 31st. Ventas’s payout ratio is currently 385.19%.

Analyst Upgrades and Downgrades

VTR has been the subject of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $93.00 target price on shares of Ventas in a report on Monday, December 15th. UBS Group reissued a “neutral” rating and issued a $85.00 price target on shares of Ventas in a research note on Monday, February 9th. KeyCorp boosted their price target on shares of Ventas from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. JPMorgan Chase & Co. upped their price objective on shares of Ventas from $88.00 to $93.00 and gave the company an “overweight” rating in a research note on Friday, March 20th. Finally, Scotiabank increased their price objective on shares of Ventas from $80.00 to $93.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $90.47.

Insider Buying and Selling

In related news, EVP Carey S. Roberts sold 35,532 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $85.00, for a total value of $3,020,220.00. Following the completion of the transaction, the executive vice president directly owned 72,755 shares in the company, valued at approximately $6,184,175. This represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Debra A. Cafaro sold 10,322 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $77.66, for a total value of $801,606.52. Following the sale, the chief executive officer directly owned 1,114,034 shares of the company’s stock, valued at approximately $86,515,880.44. This trade represents a 0.92% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.80% of the company’s stock.

About Ventas

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.